Cargando…

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

The objectives of this analysis were to develop a population pharmacokinetics (PK) model of durvalumab, an anti‐PD‐L1 antibody, and quantify the impact of baseline and time‐varying patient/disease characteristics on PK. Pooled data from two studies (1,409 patients providing 7,407 PK samples) were an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baverel, Paul G., Dubois, Vincent F.S., Jin, Chao Yu, Zheng, Yanan, Song, Xuyang, Jin, Xiaoping, Mukhopadhyay, Pralay, Gupta, Ashok, Dennis, Phillip A., Ben, Yong, Vicini, Paolo, Roskos, Lorin, Narwal, Rajesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887840/ https://www.ncbi.nlm.nih.gov/pubmed/29243223 http://dx.doi.org/10.1002/cpt.982

Ejemplares similares

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
por: Zheng, Yanan, et al.
Publicado: (2018)

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
por: Baverel, Paul, et al.
Publicado: (2019)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
por: Arends, Rosalinda, et al.
Publicado: (2021)

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017)

Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020)

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
por: Wang, Hanwen, et al.
Publicado: (2019)

Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models
por: Truong, Van Thuy, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total
por: Hood, John, et al.
Publicado: (2021)

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab
por: Wang, Bing, et al.
Publicado: (2017)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
por: Melillo, Giovanni, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer
por: Ly, Neang S., et al.
Publicado: (2023)

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
por: Ogasawara, Ken, et al.
Publicado: (2019)

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma
por: Singh, Dave, et al.
Publicado: (2010)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
por: Ye, Jiabu, et al.
Publicado: (2020)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Mechanistic modeling of a human IgG(4) monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG(4) in healthy volunteers
por: Wang, Bing, et al.
Publicado: (2022)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
por: O'Hara, Mark H., et al.
Publicado: (2020)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Phimosis: A rare complication of immunotherapy with durvalumab
por: Vázquez-Lavista, Luis Gabriel, et al.
Publicado: (2020)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
por: Sanderson, Emma, et al.
Publicado: (2020)

Acquired amegakaryocytic thrombocytopenia after durvalumab administration
por: Suyama, Takahiro, et al.
Publicado: (2021)

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Skin puckering and edema during durvalumab therapy
por: Olamiju, Brianna, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_re3e9v338ipajm79dh304ovanm